New Consumer Genomic Services Raise Questions About FDA Regulation | GenomeWeb
NEW YORK (GenomeWeb News) — The recent debut of consumer genomics services from Decode Genetics and 23andMe have raised questions about whether the US Food and Drug Administration will get involved in regulating the services, and if so, to what extent.
 
An FDA official said this week that while the agency is following these new services with interest, it cannot comment further at this time.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.